Russell Blair, MD
Pulmonary Disease · Willoughby, OHNPI 1134314644
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 487 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by GSK at 41.7% of the total. Reporting peaked in 2019 at $1,686 and has fallen 59.7% since, to $680 in 2024.
Across 487 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$1K
- Boehringer Ingelheim$769
- Regeneron Healthcare Solutions, Inc.$367
- Sanofi$273
- Grifols USA, LLC$247
- plus $2K from 25 others
What the payments were for
- Food & beverage$8,196100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 226 | $3,418 |
| AstraZeneca(2 entities) | 73 | $1,236 |
| Boehringer Ingelheim | 45 | $769 |
| Regeneron Healthcare Solutions, Inc. | 16 | $367 |
| Sanofi | 14 | $273 |
| Grifols USA, LLC | 14 | $247 |
| Amgen | 10 | $221 |
| Sunovion Pharmaceuticals Inc. | 17 | $219 |
| Mylan Specialty L.p. | 11 | $201 |
| Mallinckrodt Hospital Products Inc. | 8 | $194 |
| Novartis | 8 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $130 |
| Incyte Corporation | 1 | $125 |
| Merck | 5 | $114 |
| Teva Pharmaceuticals USA, Inc. | 4 | $73 |
| Nabriva Therapeutics, PLC | 4 | $64 |
| Covis Pharma GmbH | 4 | $50 |
| Electromed, Inc. | 2 | $49 |
| Philips North America LLC | 3 | $48 |
| Shire North American Group Inc | 2 | $35 |
| Genentech USA, Inc. | 2 | $34 |
| Vapotherm Inc | 1 | $27 |
| Portola Pharmaceuticals, LLC | 2 | $26 |
| Harmony Biosciences LLC | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Inogen, Inc. | 1 | $17 |
| Baxter Healthcare | 1 | $17 |
| Shionogi Inc | 1 | $16 |
| Pfizer | 1 | $15 |
| Circassia Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$243
- JAKAFI$125
- DUPIXENT$125
- AREXVY$120
- NUCALA$110
How this compares
$8,196 in reported general payments places this provider in the 80th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 356 | $266,449 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 77 | $53,509 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 72 | $46,744 |
| Spiriva RespimatTiotropium Bromide | 47 | $37,399 |
| Breo ElliptaFluticasone/Vilanterol | 66 | $37,066 |
| SymbicortBudesonide/Formoterol Fumarate | 45 | $13,265 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 270 | $5,242 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $5,015 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $2,611 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $2,058 |
| Ventolin HfaAlbuterol Sulfate | 32 | $1,709 |
| Theophylline ErTheophylline Anhydrous | 15 | $1,496 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $519 |
| Fluticasone Propionate | 41 | $519 |
| Prednisone | 76 | $341 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $3,418 | $350,259494 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,236 | $66,774122 claims |
| Boehringer IngelheimSpiriva Respimat | $769 | $37,39947 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Willoughby
- Joseph KhabbazaAkron$655K
- Robert BaughmanCincinnati$640K
- Kristin HighlandCleveland$551K
- Bruce CorserCincinnati$502K
- Jason StieneckerLima$397K
- Mohammad SheattCincinnati$389K
- Mohammad KhanAkron$388K
- Thomas YungerDayton$353K
- Joseph CiceniaCleveland$350K
- Jean ElwingCincinnati$320K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.